Journal Browser

Journal Browser

Frontiers in Pentadecapeptide BPC 157

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: closed (31 July 2021) | Viewed by 1084

Special Issue Editors

E-Mail Website
Guest Editor
Department of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia
Interests: gastrointestinal tract; CNS; cytoprotection; blood vessels; stable gastric pentadecapeptide BPC 157
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pathology, School of Medicine, University of Zagreb, Šalata ul. 2, 10000, Zagreb, Croatia
Interests: wound healing; angiogenesis; tissue reaction to injury; carcinogenesis; metastasis
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Oral Biology, Semmelweis University, Nagyvárad Square 4, H-1089 Budapest, Hungary
Interests: GI epithelial function; molecular physiology; stem cell research and regenerative medicine of oral structures; tissue engineering applications
Special Issues, Collections and Topics in MDPI journals

Guest Editor
Digestive Disease Center, CHA Bundang Medical Center, CHA University School of Medicine, 120 Haeryong-ro, Seongnam, Korea
Interests: gastric cytoprotection; inflammation and resolution; cancer prevention
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This special issue deals with a native gastric peptide, resistant and stable in the human gastric juice, membrane stabilizer, counteracting gut-leaky syndrome, the stable gastric pentadecapeptide BPC 157, as a particular target, distinctive from the standard peptide growth factors, with particular molecular pathways involved, controlling VEGF- and NO-pathways. In the early 1990s, pentadecapeptide BPC 157 appeared as a late outbreak of the Robert’s and Szabo’s cytoprotection - organoprotection concept, and previous theoretical/practical breakthrough in the 1980s, and brain-gut axis and gut-brain axis, and as the time went on, with its reported effects, likely most useful confirmation of theory in practical implementation and justification. Against various noxious agents causing direct cell injury, the epithelial and endothelial integrity maintenance in the stomach (cytoprotection) and in the other tissues (organoprotection) was not fully realized with the standard cytoprotective agents (i.e., prostaglandins, before sulfhydrils, CRF, EGF, somatostatin, and dopamine agonists) acting through cytoprotective defensive system. As novel mediator, BPC 157 was coming after the evidenced point of their limited beneficial effects, and NO-system importance widely introduced, but vigorously established interconnection with these important systems (i.e., prostaglandins, dopamine, serotonin, NO). Thereby, BPC 157 therapy has pleiotropic beneficial effect. In addition to the beneficial effect on the entire gastrointestinal tract, and other organs various agents- and/or noxious procedures-induced lesions (liver (cirrhosis), lung, heart, spinal cord and brain), and considerable wound healing (i.e., skin, muscle, tendon, ligament, bone) (and especial wound, i.e., corneal ulcer), it  may include counteraction of the depression-models, schizophrenia positive symptom-models and catalepsy-models. Recently, BPC 157 counteracts the vascular occlusion disturbances and blood pressure disturbances (relieving a Virchow's triad (endothelium lesions, hypercoagulability, stasis) situation) by rapid activation of the collateral vessel pathways.

You may choose our Joint Special Issue in Biomedicines, or Joint Special Issue in Current Issues in Molecular Biology.

Prof. Dr. Predrag Sikiric
Prof. Dr. Sven Seiwerth
Prof. Dr. Gábor Varga
Prof. Dr. Ki-Baik Hahm
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Cytoprotection
  • Gastric pentadecapeptide BPC 157
  • Peptides, Healing
  • Tissues lesions
  • Blood vessels lesions
  • Wounds
  • Brain-gut axis
  • Inflammation and resolution
  • Cancer prevention
  • Therapy

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop